CN Patent

CN1617712A — 速激肽受体拮抗剂的药用纳米粒组合物

Assigned to Merck Sharp and Dohme BV · Expires 2005-05-18 · 21y expired

What this patent protects

本发明涉及化合物2－(R)－(1－(R)－(3，5－双(三氟甲基)苯基)乙氧基)－3－(S)－(4－氟)苯基－4－(3－(5－氧代－1H，4H－1，2，4－三唑并)甲基吗啉的新型药用组合物。本发明的药用组合物用于治疗或预防诸如精神病等疾病，包括抑郁症和焦虑症、炎性疾病和呕吐。

USPTO Abstract

本发明涉及化合物2－(R)－(1－(R)－(3，5－双(三氟甲基)苯基)乙氧基)－3－(S)－(4－氟)苯基－4－(3－(5－氧代－1H，4H－1，2，4－三唑并)甲基吗啉的新型药用组合物。本发明的药用组合物用于治疗或预防诸如精神病等疾病，包括抑郁症和焦虑症、炎性疾病和呕吐。

Drugs covered by this patent

Patent Metadata

Patent number
CN1617712A
Jurisdiction
CN
Classification
—
Expires
2005-05-18
Drug substance claim
No
Drug product claim
No
Assignee
Merck Sharp and Dohme BV
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.